UroGen Pharma Ltd.

10.54
-0.66 (-5.89%)
At close: Apr 03, 2025, 3:59 PM
10.53
-0.14%
After-hours: Apr 03, 2025, 04:05 PM EDT
-5.89%
Bid 9.04
Market Cap 444.99M
Revenue (ttm) n/a
Net Income (ttm) n/a
EPS (ttm) -2.96
PE Ratio (ttm) -3.56
Forward PE -3.98
Analyst Buy
Ask 13.24
Volume 490,378
Avg. Volume (20D) 383,081
Open 10.78
Previous Close 11.20
Day's Range 10.29 - 11.11
52-Week Range 9.03 - 20.70
Beta 0.81

About URGN

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102, which is in Phase III clinical trials for the treatment of several forms...

Industry Biotechnology
Sector Healthcare
IPO Date May 4, 2017
Employees 235
Stock Exchange NASDAQ
Ticker Symbol URGN
Full Company Profile

Analyst Forecast

According to 6 analyst ratings, the average rating for URGN stock is "Buy." The 12-month stock price forecast is $35.5, which is an increase of 236.65% from the latest price.

Stock Forecasts

Next Earnings Release

UroGen Pharma Ltd. is scheduled to release its earnings on May 12, 2025, before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
2 months ago
+4.63%
UroGen Pharma shares are trading higher after the ... Unlock content with Pro Subscription
5 months ago
+0%
UroGen Pharma shares are trading higher after the company announced FDA acceptance of its new drug application for UGN-102.